ADRB3 and obesity disorder: Previous studies show that selective β2- or β3-AR agonists have great promise for the treatment of obesity owing to their intrinsic capacity to enhance energy expenditure in humans upon both acute and chronic treatments [16,21,[59], [60], [61]].